Curis, Inc. (CRIS) Announces Re-Initiation Of Patient Dosing In CUDC-427 Monotherapy Clinical Trial
6/5/2014 9:27:25 AM
LEXINGTON, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that it has re-initiated dosing in the single-agent clinical trial of CUDC-427 in patients with advanced and/or refractory solid tumors or lymphomas. CUDC-427 is a novel, oral small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins that support survival of cancer cells.
Help employers find you! Check out all the jobs and post your resume.
comments powered by